摘要
目的 制备放射免疫导向药物用以诊断和治疗膀胱癌。 方法 通过 2 巯基直接还原标记法将放射性核素188Re(188铼 )标记抗人膀胱癌单克隆抗体BDI 1,标记产物188Re BDI 1经尾静脉注入荷人膀胱癌裸鼠体内 ,检测其在裸鼠体内的放射性分布。 结果 188Re BDI 1的标记率为30 % ,放射化学纯度为 90 % ,免疫活性分数为 5 8.6 8%。在裸鼠体内 ,肿瘤对188Re BDI 1的摄取率在2 3h达到高峰 ,以后随时间推移 ,逐步下降。 2 3h时T/NT比值 (肿瘤与正常组织的放射性计数之比 )明显增加 ,平均T/NT为 4.42 ,最大为 16 .19(肿瘤 /肌肉 ) ,随时间推移T/NT比值有所下降 ,48h时T/NT比值仍保持在高水平 10 .41(肿瘤 /肌肉 )、70h时T/NT比值 3.41(肿瘤 /肌肉 )。结论 188Re BDI 1在裸鼠体内对膀胱癌移植瘤有靶向定位作用。188Re BDI 1有可能成为膀胱癌放射免疫显像和治疗的导向药物。
Objective To make use of 188 Re BDI 1 in the diagnosis and treatment of bladder cancer. Methods Anti human bladder cancer monoclonal antibody BDI 1 was labeled with rhenium 188 by direct 2 mercaptoethanol reduction method. 188 Re BDI 1 was injected through tail vein of nude mice xenografted with human bladder cancer and the biodistribution of 188 Re BDI 1 were studied. Results The labeling yield of BDI 1 was 30%, the radiochemical purity of the labeled antibody 188 Re BDI 1 was 90%, and the inmmunoreactive fraction was 58.68%. The tumor’s %ID/g (percentage of the injected dose per gram of tissue) at 23h postinjection got to the peak. With time elasped, the tumor’s %ID/g was gradually decreased. T/NT (radio counts of tumor vs normal tissue) was obviously increasing in 23h, the average T/NT being 4.42, and the maximum 16.19 (tumor/muscle). T/NT was 10.14 at 48 h and 3.41 at 70 h. Conclusions The results indicated that 188 Re BDI 1 can be located to xenografted human bladder cancer and can be used for radioimmunodetection of human bladder carcinoma in vivo.
出处
《中华泌尿外科杂志》
CSCD
北大核心
2000年第7期415-417,共3页
Chinese Journal of Urology
基金
卫生部直属单位临床学科重点项目资金资助!(970202 15 )
